Ambrilia files for bankruptcy protection; MSM collaborates on new antibodies;

> Two days after laying off its CEO and CFO, the struggling Canadian biotech Ambrilia filed for bankruptcy protection. The biotech says that it does not have enough cash on hand to meet its obligations. Report

> Genentech's eye drug Lucentis proved effective in a late-stage trial of central retinal vein occlusion. Report

> MSM Protein Technologies is teaming with Merck KGaA and Debiopharm to create antibodies that can influence G-protein coupled receptors and similar targets. Story

> Chiesi Farmaceutici has completed a deal to buy a majority stake in Cary, NC-based Cornerstone Therapeutics. Story

> Sirona Biochem says it has begun work on a batch of molecules for diabetes and obesity. Release

> Greece says it plans to vaccinate its entire population against swine flu. The country has already inked new contracts with Novartis and Sanofi. Report

Pharma News

> Merck KGaA wants a redo. The German drugmaker is appealing last week's rejection of Erbitux as a lung-cancer treatment, hoping that it can get the nod for at least a subset of those patients. Report

> Swine flu could be MedImmune's watershed moment. The company says it's gearing up to produce about five times as much H1N1 flu vaccine as it had expected, the New York Times reports. Report

> A House committee has defanged comparative effectiveness. In an amendment added to the healthcare reform bill, lawmakers stipulate that the government can't use the research to dictate care. Report

And Finally... A House committee has defanged comparative effectiveness. In an amendment added to the healthcare reform bill, lawmakers stipulate that the government can't use the research to dictate care. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.